Features of responding to stress of elderly patients with chronic brain ischemia

The aim of the study. To study the peculiarities of responding to stress, the stress resistance and adaptation of older men and women with chronic brain ischemia, as well as the stressboard effect of Mexidol.
Material and methods. 124 patients aged 60–74 years old are surveyed: 72 men and 52 women (average age, respectively, 65.3 ± 0.4 and 64.7 ± 0.7 years) with Chronic Brain Ischemia I–II stage against the background of arterial hypertension and its combinations with atherosclerosis of cerebral vessels. The level of psychosocial stress was determined on the Holmes-Ray scale. Features of the response of patients to stress was studied using the methodology Scale of Psychological Stress PSM-25 and S. Rogenzweig. Stress resistance was investigated using S. Kuhlen's stress resistance self-resistant test and Villianson. The level of anxiety was determined using a scale of Ch.D. Spilberger and Yu.L. Khanin, depressed – backup questionnaire. The type of adaptation reactions was studied in the leukocyte blood formula on the percentage ratio of lymphocytes and segmented neutrophils, taking into account the representation of other formed elements.
Results. The level of stress in older women with Chronic Brain Ischemia was higher than in men. The predominance of the intrinsic orientation of the reaction to stress and resolving the type of response to men, and the extrapunitive or self-defense type among women, which may indicate the largerness of the latter. The level of stress resistance was lower in women than in men, which correlated with higher indicators of situational anxiety. Adverse adaptation reactions were more often registered in women than in men. The course of treatment with Mexidol of elderly patients with chemical leads to a decrease in the severity of subjective and objective symptoms, alarming disorders, increases the stress resistance and adaptive capabilities of the body, which is confrmed by an increase in the number of persons with favorable adaptation reactions. The high effciency and safety of sequential therapy with Mexidol (injections, then the tableted form of Mexidol Forte 250) is shown.

1. Damulin I. V. Dyscirculatory encephalopathy: pathogenesis, clinical picture, treatment: guidelines. M.: Media Sfera, 2005. 48 p. (In Russ.)

2. Levin OS. Diagnosis and treatment of dyscirculatory encephalopathy. Method. beneft. M. 2010. (In Russ.)

3. Chukanova EI, Chukanova AS. Chronic brain ischemia (risk factors, pathogenesis, clinic, treatment). Methodical recommendation. M. 2015. (In Russ.)

4. Gusev EI, Chukanova EI, Chukanova AS. Chronic cerebrovascular insuffciency (risk factors, pathogenesis, clinic, treatment). M.: Act 345; 2018. (In Russ.)

5. Kadykov AS, Manvelov LS, Shahparonova NI. Chronic vascular diseases of the brain encephalopathy. Guide for doctors. 3rd edition, revised and expanded. M.: GEOTAR-Media; 2014. (In Russ.)

6. Voznesenskaya TG. Emotional stress and prevention of its consequences. Russian Medical Journal. 2006; 14 (9): 694–697. (In Russ.)

7. Dyukova G.M. Depression in elderly neurological patients: diagnosis and treatment. Clinical Gerontology. 2008. No. 3. P. 67–75. (In Russ.)

8. Schumacher G.I. et al. Depressive disorders in patients with stage I–II discirculatory encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry: application «Stroke». 2007. P. 371–372. (In Russ.)

9. Vein A.M., Danilov A.B. Gender problem in neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2003. No. 10. P. 4–14. (In Russ.)

10. Verkin AL. et al. Gender approaches to the treatment of cardiovascular pathology: a man in the center of attention. Russian Medical Journal. Special issue. Pain syndrome. 2008: 17–20. (In Russ.)

11. Kalinkin M.N., Yakovlev N.A., Slyusar T.A. Chronic cerebral ischemia in old age (pathogenetic and clinical aspects). Tver: RITs TSMU, 2016. 226 p. (In Russ.)

12. Abramenko Y., Iakovlev N., Slyusar T. Comparative characteristics of cognitive disorders in stroke in men. Journal of Neurology. Vol. 260, Suppl. 1, June 2013. Р. 214–215.

13. Voronina TA Pioneer antioxidant neuroprotection. 20 years in clinical practice. Russian Medical Journal. 2016; 7: 434–438. (In Russ.)

14. Rumyantseva SA., Kravchuk AA., Silina EV. Antioxidants in cerebrovascular disease therapy. Attending physician. 2006; 5: 42–47. (In Russ.)

15. Suslin ZA., Smirnova IN., Tanashyan MM. et al. Mexidol with chronic forms of cerebrovascular diseases. Treatment of nerve diseases. 2002; 3: 28–33. (In Russ.)

16. Smirnova IN., Fedorova TN., Tanashyan MM., Suslin ZA. Clinical effcacy and antioxidant activity of mexidol in chronic cerebrovascular diseases. Atmosphere. Nervous diseases. 2006; 1: 33–36. (In Russ.)

17. Chukanova EI., Chukanova AS. Effciency and safety of drug Mexidol Forte 250 as part of successive therapy in patients with chronic brain ischemia. Magazine of neurology and psychiatry. S.S. Korsakov. 2019; 119 (9): 39–45. (In Russ.)

18. Duma SN. Possibilities of antioxidant therapy in asthenia and cognitive defcits in elderly patients with chronic brain ischemia. Therapeutic Archive. 2013; 12: 100–105. (In Russ.)

19. Voronina TA Mexidol. Main neuropsychotropic effects and action mechanism. Pharmatek. 2009; 180 (6): 1–4. (In Russ.)

20. Drozdova TV, Fitmova OA, Fitmova AA. The Role of Mexidol in the treatment of moderate cognitive disorders in the framework of the manifestations of chronic cerebrovascular insuffciency. Pharmateca. 2012; 14: 97–103.

21. Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii im.S.S. Korsakova. 2016; 116 (4): 28–31. (In Russ.)

22. Holmes T.H., Rahe R.H. The Social Readjustment Rating Scale. J. of Phychosom Research.1967. Vol. 11. P. 213–218.

23. Kupriyanov RV., Kuzmin Yu M. Psychodiagnostic stress. Kazan. 2012: 212. (In Russ.)

24. Eliseev O.P. Workshop on personality psychology. SPB, 2000. (In Russ.)

25. Scherbatykh Yu.V. Psychology of stress. M., 2005. (In Russ.)

26. Spilberger С. D. et al. Manual for the State-Trait Anxiety Inventory. Palo Alto, 1970. 38 p.

27. Belova AN. Scales, tests, questionnaires in neurology and neurosurgery. M.: Antidor; 2004. (In Russ.)

28. Beck А.Т. et al. An inventory for measuring depression. Arch. Gen Psychiatr. 1961. Vol. 5. P. 561–571.

29. Garkavi L. Kh., Kvakina E. B., Ukolova M. A. Adaptive reactions and body resistance. Rostov-on-Don, 1977. 273 p. (In Russ.)

30. Brazhenko N.A., Brazhenko O.N., Trofmov V.I. Adaptive reactions of the body and ways to improve the effectiveness of treatment in modern conditions. New St. Petersburg Medical Bulletin. 2002. No. 2. P. 49–53. (In Russ.)

31. Antiphenko EA., Troshin VV., Dryugina AV. et al. Non-specifc resistance of the body in chronic brain ischemia. Medical almanac. 2011; 1 (14): 60–62. (In Russ.)

32. Vlasova I.A. Reactions of adaptation and the functional condition of the organism of elderly persons. Sib. Med. J., 2012, No. 6. С. 46–50.

33. Kitaev-Smyk DA. Psychology of stress. M., 1983. (In Russ.)

34. Greenberg J. Stress Management. St. Petersburg, 2002. (In Russ.)

35. Bendas T.V. Gender Psychology. SPb.: Peter. 2006. 431 р. (In Russ.)